Four additional patients (two with ER-positive, one with HER2-positive, and one with triple-negative breast cancer) exhibited a PR to treatment, and the remaining 12 evaluable patients experienced SD, suggesting potential clinical activity. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.